- To serve as an important medium for the publication of original research in the field of medical science and health research, thus filling gaps in health knowledge for effective utilization of research findings
- To impart current medical knowledge and updated scientific information obtained from research to health professionals for better and appropriate health care management
- To disseminate recent basic, applied and social research findings among health personnel of different strata for enhancing worldwide health development
Archives 2005
Myanmar Health Sciences Research Journal
Volume 17, Number 3
TITLE: A preliminary study of the immune response to locally produced recombinant hepatitis B vaccine in adult volunteers.
AUTHOR: Khin May Oo; Moh Moh Htun; Win Maw Tun; Kyin Kyin San; Nyein Nyein; Kay Khine Soe; Tin Tin Myint; Khin Pyone Kyi
SOURCE: Myanmar Health Sciences Research Journal. 2005; 17(3): 154-158
ABSTRACT: The immune response to locally produced recombinant hepatitis B vaccine was studied on 17 male adult volunteers.All subjects were negative for the hepatitis B markers namely hepatitis B surface antigen (HBsAg) and antibody to HBsAg (anti-HBs).Three doses of recombinant hepatitis B vaccine were given at 0, 1, 2 month intervals by intramuscular (IM) route.Eleven subjects were given 3 vaccinations of 20ïÂÂg per dose and 6 subjects were vaccinated with 40ïÂÂg of recombinant hepatitis B vaccine as the initial dose and 20ïÂÂg for the subsequent second and third doses.Blood samples were collected from each subject at 1, 2, 3 month intervals and tested for the presence of anti-HBs using the SD Anti-HBs ELISA 3.0, Standard Diagnostic, Korea.A known anti-HBs positive serum (400 m IU/ml) was used as the Working Standard.Anti-HBs was present in 23.5% of subjects one month after the first dose, 52.9% after the second dose and 88.2% after the third dose. The anti-HBs values ranged from 2 - 72 m IU/ml and protective anti-HBs levels (more than 10 m IU/ml) were achieved in 76.5% of the vaccinees at the end of 3 months.From this preliminary study, it could be concluded that the locally produced recombinant hepatitis B vaccine is immunogenic in human subjects.
SUBJECT HEADINGS: Hepatitis B Vaccines.
FULL TEXT: